Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects
Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Summary
To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2023-10-13
Completion Date
2024-09-13
Last Updated
2026-10-13
Healthy Volunteers
No
Conditions
Interventions
BGM0504
Administered SC
BGM0504
Administered SC
BGM0504
Administered SC
Placebo
Administered SC
Locations (1)
The Third Xiangya Hospital of Central South University
Changsha, China